FDA-approved peptide medicines

Approval follows the diagnosis.

Peptide-based medicines are prescription drugs tied to specific labeled conditions—not a generic shortcut for anti-aging, recovery, bodybuilding, or rapid fat loss.

Start licensed provider review Review care paths

Prescription required. An independent licensed provider reviews your medical history and decides whether treatment is appropriate. Not everyone qualifies.

Licensed provider reviewing prescribing information and a patient chart — Quenva care, in contextProduct status and labeled indication come before any treatment discussion.

Potential care paths

Options, with the status visible.

The word “peptide” describes a molecular structure; it does not prove that a product or use is FDA-approved. Quenva separates labeled medicines, off-label decisions, compounded products, and research-only substances.

01 · Metabolic medicine

GLP-1 & GIP pathways

FDA-approved products exist for specific indications

Semaglutide, tirzepatide, and related peptide-based medicines belong in the Weight Care pathway, where diagnosis, label, access, and safety can be reviewed clearly.

Review condition-specific warnings, contraindications, interactions, and urgent symptoms before care.

Safety Information

02 · Specialist pathway

Tesamorelin

FDA-approved for HIV-associated lipodystrophy · not general weight loss

EGRIFTA SV® is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

Review condition-specific warnings, contraindications, interactions, and urgent symptoms before care.

Safety Information

03 · Rare-disease pathway

Setmelanotide

FDA-approved only for qualifying rare genetic obesity disorders

IMCIVREE® is a specialist medicine for patients whose obesity is caused by specific qualifying genetic conditions.

Review condition-specific warnings, contraindications, interactions, and urgent symptoms before care.

Safety Information

Named medicines are examples a licensed provider may discuss. They do not guarantee that Quenva currently offers the product, that it is available in your state, or that a prescription will be issued.

The approval path

Molecule. Product. Indication. Patient.

Each step matters. A peptide-based medicine is responsibly discussed only when its exact product status and indication match the clinical conversation.

01Verify the product

02Match the indication

03Confirm specialist care

What shapes the decision

Care begins with context.

Online convenience does not reduce the standard of clinical review. A licensed provider may request records, testing, a phone or video visit, or local evaluation.

Exact diagnosis and labeled indicationCommercial product versus compounded preparationSpecialist oversightLaboratory and monitoring needsState and pharmacy availabilityManufacturer safety information

Safety

Research peptides are not approved therapies.

Detailed safety information and official medication resources are centralized for clarity. Review the relevant section before beginning a licensed provider evaluation.

Review Approved Peptides Safety Information

Begin privately

A licensed provider reviews the full picture.

Program availability, price, required visits, tests, and medication options are confirmed before you authorize treatment.

See if care may fit